Doryx Dosage

Generic name: Doxycycline Delayed-Release Tablets
Drug classes: Miscellaneous antimalarials, Tetracyclines

Medically reviewed by  A Ras MD.

 

Recommended Adult Dosing

Dosage forms:  DR TAB: 50 mg, 200 mg

Infections, mild-moderate bacterial

[100 mg PO qd]

Start: 100 mg PO bid x1 day; Info: duration varies by indication; may break tab, but do not chew/crush contents

Infections, severe bacterial

[100 mg PO bid]

Info: duration varies by indication; may break tab, but do not chew/crush contents

Severe acne vulgaris, adjunct tx

[50-100 mg PO qd-bid]

Info: may break tab, but do not chew/crush contents

Pneumonia, community-acquired

[100 mg PO q12h for at least 5 days]

Info: refer to IDSA guidelines; may break tab, but do not chew/crush contents

Sinusitis, acute bacterial

[200 mg/day PO divided q12-24h x5-7 days]

Info: may break tab, but do not chew/crush contents

Infections, chlamydial

[treatment]

Dose: 100 mg PO q12h x7 days; Info: 1st-line agent; may break tab, but do not chew/crush contents

[*presumptive tx]

Dose: 100 mg PO q12h x7 days; Info: for sexual assault victims; give w/ ceftriaxone and metronidazole in female pts; give w/ ceftriaxone in male pts; may break tab, but do not chew/crush contents

Syphilis

[primary, secondary, or latent <1y]

Dose: 100 mg PO q12h x14 days; Info: for pts w/ hypersens. to PCN; not 1st-line agent; may break tab, but do not chew/crush contents

[latent >1y or unknown duration]

Dose: 100 mg PO q12h x28 days; Info: for pts w/ hypersens. to PCN; not 1st-line agent; may break tab, but do not chew/crush contents

Lymphogranuloma venereum

[100 mg PO q12h x21 days]

Info: may give for 7 days if asymptomatic dz; 1st-line agent; may break tab, but do not chew/crush contents

Urethritis, non-gonococcal

[100 mg PO q12h x7 days]

Info: 1st-line agent; may break tab, but do not chew/crush contents

Epididymitis

[100 mg PO q12h x10 days]

Info: give w/ ceftriaxone; may break tab, but do not chew/crush contents

Proctitis

[100 mg PO q12h x7 days]

Info: give w/ ceftriaxone; extend duration to 21 days if positive rectal chlamydia test w/ bloody discharge, perianal or mucosal ulcers, or tenesmus; may break tab, but do not chew/crush contents

Anthrax

[systemic]

Dose: 100 mg PO q12h; Start: use after IV tx; Info: not recommended for CNS anthrax; may use in pregnant women; not 1st-line agent; part of multi-drug regimen; continue abx for post-exposure prophylaxis if inhalational exposure; may break tab, but do not chew/crush contents

[cutaneous]

Dose: 100 mg PO q12h x7-10 days; Info: for non-systemic infection; 1st-line agent; use extended duration for post-exposure prophylaxis if bioterrorism suspected; may use in pregnant women; may break tab, but do not chew/crush contents

[post-exposure prophylaxis]

Dose: 100 mg PO q12h x60 days; Info: 1st-line agent; give in combo w/ anthrax vaccine; may use in pregnant women; may break tab, but do not chew/crush contents; may give x42 days, or x14 days after last vaccine dose, in immunocompetent pts 18-65 yo if anthrax vaccine regimen completed

Malaria prophylaxis

[100 mg PO qd]

Start: 1-2 days before exposure; Info: may break tab, but do not chew/crush contents; D/C 4wk after exposure; see CDC Pre-Travel Malaria Prophylaxis recommendations in Guidelines > Specialties > Infectious Diseases

Tularemia

[100 mg PO q12h x14-21 days]

Info: may break tab, but do not chew/crush contents

Rocky Mountain spotted fever

[100 mg PO q12h x5-14 days]

Info: may break tab, but do not chew/crush contents

Cholera

[300 mg PO x1]

Info: may break tab, but do not chew/crush contents

Brucellosis

[100 mg PO q12h x6wk]

Info: part of multi-drug regimen; may break tab, but do not chew/crush contents

PID

[mild-moderate infection]

Dose: 100 mg PO q12h x14 days; Info: give w/ ceftriaxone and metronidazole, cefotaxime and metronidazole, or cefoxitin plus probenecid and metronidazole; 1st-line agent; may break tab, but do not chew/crush contents

[severe infection]

Dose: 100 mg PO q12h x14 days; Info: give w/ ceftriaxone plus metronidazole, cefotetan, cefoxitin, ampicillin/sulbactam, or cefotaxime plus metronidazole; 1st-line agent; may break tab, but do not chew/crush contents

Lyme disease

[100 mg PO q12h x14-21 days]

Alt: 200 mg q24h x14-21 days; Info: may give for 10-14 days if early, localized dz; extend duration to 28 days if Lyme arthritis; 1st-line agent; may break tab, but do not chew/crush contents; search ‘Lyme’ for epocrates Lyme Disease Dx & Tx decision tool

Lyme disease prophylaxis, post-exposure

[200 mg PO x1 dose]

Start: w/in 72h of tick removal after high-risk bite; Info: may break tab, but do not chew/crush contents; search ‘Lyme’ for epocrates Lyme Disease Dx & Tx decision tool

Cervicitis, presumptive

[100 mg PO q12h x7 days]

Info: 1st-line agent; may break tab, but do not chew/crush contents

Mycoplasma genitalium infection

[macrolide-susceptible]

Dose: 100 mg PO q12h x7 days; Info: follow w/ azithromycin 1 g PO x1, then 500 mg PO qd x3 days; may break tab, but do not chew/crush contents

[macrolide-resistant or resistance unknown]

Dose: 100 mg PO q12h x7 days; Info: follow w/ moxifloxacin 400 mg PO qd x7 days; may break tab, but do not chew/crush contents

Granuloma inguinale

[100 mg PO q12h for at least 3wk]

Info: may extend tx if not healed after 3wk; not 1st-line agent; may break tab, but do not chew/crush contents

H. pylori infection

[100 mg PO qd x7-10 days]

Info: part of multi-drug regimen; search H. pylori Tx Regimens for guidelines; may break tab, but do not chew/crush contents

Malaria tx, uncomplicated

[100 mg PO q12h x7 days]

Info: give w/ quinine sulfate; follow up tx w/ primaquine to avoid relapse in acute P. vivax or P. ovale infection; refer to CDC guidelines; may break tab, but do not chew/crush contents

Non-cholera vibrio infection, gastroenteritis

[100 mg PO q12h x3 days]

Info: for diarrhea persisting >5 days; may break tab, but do not chew/crush contents

Anaplasmosis

[100 mg PO q12h x10-14 days]

Info: may break tab, but do not chew/crush contents

Ehrlichiosis

[100 mg PO q12h x5-14 days]

Info: may break tab, but do not chew/crush contents

Onchocerciasis

[200 mg PO qd x6wk]

Start: 1wk after ivermectin tx; Info: may decr. to 100 mg PO qd if not tolerated; not 1st-line agent; may break tab, but do not chew/crush contents

Renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

Hepatic dosing

[not defined]

Recommended Peds Dosing

Dosage forms:  DR TAB: 50 mg, 200 mg

Infections, mild-moderate bacterial

[>8 yo]

Dose: 2.2 mg/kg/dose PO qd; Start: 2.2 mg/kg/dose PO bid x1 day; Max: 100 mg/dose; Info: duration varies by indication; may break tab, but do not chew/crush contents

Infections, severe bacterial

[>8 yo]

Dose: 2.2 mg/kg/dose PO bid; Max: 100 mg/dose; Info: duration varies by indication; may break tab, but do not chew/crush contents

Severe acne vulgaris, adjunct tx

[>8 yo]

Dose: 2.2 mg/kg/dose PO qd; Start: 2.2 mg/kg/dose PO bid x1 day; Max: 100 mg/dose; Info: may break tab, but do not chew/crush contents

Community-acquired pneumonia, atypical

[>8 yo]

Dose: 2.2-4.4 mg/kg/day PO divided q12h x7-10 days; Info: may break tab, but do not chew/crush contents

Infections, chlamydial

[treatment, 8 yo and older]

Dose: 100 mg PO q12h x7 days; Info: 1st-line agent; may break tab, but do not chew/crush contents

[*presumptive tx, 8 yo and older]

Dose: 100 mg PO q12h x7 days; Info: for sexual assault victims; give w/ ceftriaxone and metronidazole in female pts; give w/ ceftriaxone in male pts; may break tab, but do not chew/crush contents

Syphilis

[primary, secondary, or latent <1y, adolescents]

Dose: 100 mg PO q12h x14 days; Info: for pts w/ hypersens. to PCN; not 1st-line agent; may break tab, but do not chew/crush contents

[latent >1y or unknown duration, adolescents]

Dose: 100 mg PO q12h x28 days; Info: for pts w/ hypersens. to PCN; not 1st-line agent; may break tab, but do not chew/crush contents

Lymphogranuloma venereum

[preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x21 days; Info: may give for 7 days if asymptomatic dz; 1st-line agent; may break tab, but do not chew/crush contents

Urethritis, non-gonococcal

[preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x7 days; Info: 1st-line agent; may break tab, but do not chew/crush contents

Epididymitis

[preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x10 days; Info: give w/ ceftriaxone; may break tab, but do not chew/crush contents

Proctitis

[preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x7 days; Info: give w/ ceftriaxone; extend duration to 21 days if positive rectal chlamydia test w/ bloody discharge, perianal or mucosal ulcers, or tenesmus; may break tab, but do not chew/crush contents

Anthrax

[systemic]

Dose: 2.2 mg/kg/dose PO q12h; Start: use after IV tx; Max: 100 mg/dose; Info: not recommended for CNS anthrax; not 1st-line agent; part of multi-drug regimen; give x60 days total if inhalational exposure; may break tab, but do not chew/crush contents

[cutaneous]

Dose: 2.2 mg/kg/dose PO q12h x7-10 days; Max: 100 mg/dose; Info: for non-systemic infection; give abx x60 days total if bioterrorism suspected; may break tab, but do not chew/crush contents

[post-exposure prophylaxis]

Dose: 2.2 mg/kg/dose PO q12h x60 days; Max: 100 mg/dose; Info: 1st-line agent; may break tab, but do not chew/crush contents

Malaria prophylaxis

[>8 yo]

Dose: 2.2 mg/kg/dose PO qd; Start: 1-2 days before exposure; Max: 100 mg/day; Info: may break tab, but do not chew/crush contents; D/C 4wk after exposure; see CDC Pre-Travel Malaria Prophylaxis recommendations in Guidelines > Specialties > Infectious Diseases

Rocky Mountain spotted fever

[2.2 mg/kg/dose PO q12h x5-14 days]

Max: 100 mg/dose; Info: may break tab, but do not chew/crush contents

Cholera

[>8 yo]

Dose: 4.4-6.6 mg/kg/dose PO x1; Max: 300 mg/dose; Info: may break tab, but do not chew/crush contents

Brucellosis

[>8 yo]

Dose: 100 mg PO q12h x6wk; Info: part of multi-drug regimen; may break tab, but do not chew/crush contents

PID

[mild-moderate infection, preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x14 days; Info: give w/ ceftriaxone and metronidazole, cefotaxime and metronidazole, or cefoxitin plus probenecid and metronidazole; 1st-line agent; may break tab, but do not chew/crush contents

[severe infection, preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x14 days; Info: give w/ ceftriaxone plus metronidazole, cefotetan, cefoxitin, ampicillin/sulbactam, or cefotaxime plus metronidazole; 1st-line agent; may break tab, but do not chew/crush contents

Lyme disease

[2.2 mg/kg/dose PO q12h x14-21 days]

Max: 100 mg/dose; Info: may give for 10-14 days if early, localized dz; extend duration to 28 days if Lyme arthritis; 1st-line agent; may break tab, but do not chew/crush contents; search ‘Lyme’ for epocrates Lyme Disease Dx & Tx decision tool

Lyme disease prophylaxis, post-exposure

[4.4 mg/kg/dose PO x1 dose]

Start: w/in 72h of tick removal after high-risk bite; Max: 200 mg/dose; Info: may break tab, but do not chew/crush contents; search ‘Lyme’ for epocrates Lyme Disease Dx & Tx decision tool

Cervicitis, presumptive

[preadolescents >45 kg and adolescents]

Dose: 100 mg PO q12h x7 days; Info: 1st-line agent; may break tab, but do not chew/crush contents

Mycoplasma genitalium infection

[macrolide-susceptible, adolescents]

Dose: 100 mg PO q12h x7 days; Info: follow w/ azithromycin 1 g PO x1, then 500 mg PO qd x3 days; may break tab, but do not chew/crush contents

[macrolide-resistant or resistance unknown, adolescents]

Dose: 100 mg PO q12h x7 days; Info: follow w/ moxifloxacin 400 mg PO qd x7 days; may break tab, but do not chew/crush contents

Granuloma inguinale

[adolescents]

Dose: 100 mg PO q12h for at least 3wk; Info: may extend tx if not healed after 3wk; not 1st-line agent; may break tab, but do not chew/crush contents

Malaria tx, uncomplicated

[2.2 mg/kg/dose PO q12h x7 days]

Max: 100 mg/dose; Info: give w/ quinine sulfate; follow up tx w/ primaquine to avoid relapse in acute P. vivax or P. ovale infection; refer to CDC guidelines; may break tab, but do not chew/crush contents

Non-cholera vibrio infection, gastroenteritis

[>8 yo, <45 kg]

Dose: 2.2 mg/kg/dose PO q12h x3 days; Max: 200 mg/day; Info: for diarrhea persisting >5 days; may break tab, but do not chew/crush contents

[>8 yo, >45 kg]

Dose: 100 mg PO q12h x3 days; Info: for diarrhea persisting >5 days; may break tab, but do not chew/crush contents

Non-cholera vibrio infection, invasive dz

[>8 yo, <45 kg]

Dose: 2.2 mg/kg/dose PO q12h; Max: 200 mg/day; Info: part of multi-drug regimen; may break tab, but do not chew/crush contents

[>8 yo, >45 kg]

Dose: 100 mg PO q12h; Info: part of multi-drug regimen; may break tab, but do not chew/crush contents

Anaplasmosis

[2.2 mg/kg/dose PO q12h x10-14 days]

Max: 100 mg/dose; Info: may break tab, but do not chew/crush contents

Ehrlichiosis

[2.2 mg/kg/dose PO q12h x5-14 days]

Max: 100 mg/dose; Info: may break tab, but do not chew/crush contents

Onchocerciasis

[200 mg PO qd x6wk]

Start: 1wk after ivermectin tx; Info: may decr. to 100 mg PO qd if not tolerated; not 1st-line agent; may break tab, but do not chew/crush contents

Renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

Hepatic dosing

[not defined]

 

SRC: NLM .